Comparison · NCT00908141-sae
Group A: Sargramostim (Days 1-14) vs Group B: Sargramostim (3 x Week): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A: Sargramostim (Days 1-14) vs Group B: Sargramostim (3 x Week): serious adverse events. Trial comparisons, record NCT00908141-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00908141-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.324 | wilson | |
| Risk in group 2 | 0.222 | 0.0632 | 0.547 | wilson | |
| Risk difference, group 1 minus group 2 | -0.222 | -0.547 | 0.139 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on Group A: Sargramostim (Days 1-14) than on Group B: Sargramostim (3 x Week) | 4.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A: Sargramostim (Days 1-14) | GROUP A:~Sargramostim 250ug/m2/day subcutaneously (s.c.) on days 1-14 of a 28-day cycle | 0 | 8 | EG000 |
| Group 2 | Group B: Sargramostim (3 x Week) | GROUP B:~Sargramostim 250ug subcutaneously (s.c.) three times a week continuously | 2 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All patients will be evaluable for toxicity from the time of their first treatment with sargramostim through follow up over an approximate three year period.
Source ClinicalTrials.gov
Trial
- Title
- GM-CSF in Treating Patients With Relapsed Prostate Cancer
- NCT number
- NCT00908141
- Phases
- PHASE2
- Conditions
- Prostate Cancer
- Interventions
- sargramostim
- Lead sponsor
- Case Comprehensive Cancer Center
- Results first posted
- 2013-08-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00908141?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00908141-sae